A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)

NCT07425522 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

93

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Macular Edema

Interventions

DRUG: RO7823653
DRUG: Faricimab

Sponsor

Genentech, Inc.